Generic diabetes combo pill put to the test
NCT ID NCT07213895
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compared a generic combination tablet containing three diabetes drugs (empagliflozin, linagliptin, and metformin) to the brand-name Trijardy XR. Fourteen healthy adults took a single dose of each under fed conditions to see if the generic is absorbed at the same rate and amount. The goal is to confirm bioequivalence, which could lead to a lower-cost option for managing type 2 diabetes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Empagliflozin, Linagliptin, and Metformin (extended-release combination tablet)
- What this could lead to
- If successful, this could lead to a more affordable generic version of the diabetes combination pill Trijardy XR.
- What could go wrong
- This is a small, early-phase study in healthy people, not patients. It only checks if the generic is absorbed similarly, not if it works better or is safer long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ACDIMA Center
Amman, 925161, Jordan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your gut bacteria hold the key to protecting your kidneys?
- Muscle-Saving supplement may shield seniors from Weight-Loss drug side effect
- Can diabetes disrupt the Brain-Heart link?
- A scent of citrus: could bitter orange oil ease fatigue and aid sleep in diabetes?
- Gut bacteria swap may tame diabetes and thyroid disease
- A blood marker may reveal how well diabetes treatments are working